WW — WW International, Inc.

WW (WeightWatchers) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Subscribers: 2.5 million, with a decline in behavioral subscribers (down 24.6% year-over-year).
• Core+ Subscribers: 541,000, up 13.9% year-over-year, marking the third consecutive quarter of growth.
• Clinical Subscribers: 197,000, up 55.7% year-over-year.
• Revenue: $162.3 million, down from $189.2 million in Q2 2025.
• Clinical Subscription Revenue: Grew 30.4% to $39.9 million, now representing 24.6% of total revenue.
• Gross Margin: 70.3%, with adjusted gross margin at 73.6%.
• Net Income: $14.1 million, including a $4.6 million gain from debt extinguishment.
• Adjusted EBITDA: $39.8 million, a margin of 24.5%, down from $65.3 million in Q2 2025.
• Cash Position: $101.5 million in cash and cash equivalents, down from $120.9 million in Q1 2026.

2. Strategic Updates and Business Highlights:

• WeightWatchers is integrating GLP-1 medications into their offerings, providing a combination of medication and expert guidance.
• Launched a collaboration with Sam's Club to expand market reach.
• Introduced a Medicare GLP-1 bridge program to enhance medication access.
• Emphasized a "people-first" approach, combining clinical care, behavioral support, and technology.
• Notable behavioral shifts include a reported 29% reduction in calories from ultra-processed foods among members.

3. Forward Guidance and Outlook:

• Reaffirmed 2026 revenue guidance of $620 million to $635 million and adjusted EBITDA of $105 million to $115 million.
• Clinical subscription revenue expected to represent 25% to 30% of total revenue for 2026.
• Anticipated continued growth in Core+ subscribers and moderation in the decline of behavioral subscribers.
• Expected positive operating cash flow for the full year 2026, with a focus on maintaining liquidity for strategic investments.

4. Bad News, Challenges, or Points of Concern:

• Behavioral subscription revenue declined significantly (down 22.7% year-over-year).
• Core tier subscribers saw a notable drop, contributing to the overall decline in behavioral subscribers.
• Marketing spend was higher than the previous year, reflecting a recalibration after a significant reduction during financial reorganization.
• Potential risks include the impact of reduced marketing spend on subscriber growth and the competitive landscape with increasing offerings of prescription medications without guidance.

5. Notable Q&A Insights:

• There were no questions during the Q&A segment, indicating either a lack of immediate investor concerns or a focus on the presented information.

Overall, WeightWatchers is navigating a transformative period, leveraging its unique combination of clinical and behavioral support while facing challenges in subscriber retention and revenue growth in certain segments. The company remains optimistic about its strategic direction and financial stability moving forward.